We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

LGC Clinical Diagnostics

LGC Clinical Diagnostics is a leading provider of Quality Measurement Tools, biological materials, and reagents for t... read more Featured Products: More products

Download Mobile App




LGC Clinical Diagnostics and AccuGenomics Collaborate on Enhancing Cancer Testing Accuracy

By LabMedica International staff writers
Posted on 11 Oct 2024

LGC (London, UK), a global leader in clinical diagnostics and genomics, and AccuGenomics (Wilmington, NC, USA), a pioneer in molecular diagnostic development, have entered into a new strategic partnership to combine LGC’s expertise in quality control solutions with AccuGenomics’ advanced NGS monitoring technologies, driving innovation in clinical diagnostic tools. More...

The companies will focus on developing highly accurate and reliable molecular diagnostics and quality control materials, fulfilling the vital needs of precision medicine and improving patient management. Through this collaboration, LGC and AccuGenomics intend to deliver enhanced solutions for cancer NGS testing quality control. LGC’s extensive clinical genomics reference material expertise, combined with AccuGenomics’ proprietary technology, will allow laboratories across the world to integrate third party controls into their procedures, ensuring more reliable, actionable patient results from NGS-based assays. Additionally, the companies will also develop custom reference materials for NGS assay validation, supporting the evolving landscape of precision diagnostics. LGC and AccuGenomics expect this collaboration to speed up the adoption of NGS technologies in clinical laboratories across the world.

“We are delighted to partner with AccuGenomics to further our mission of providing laboratories with cutting-edge quality control solutions,” said Bharathi Anekella, Executive Vice President of LGC. “This collaboration aligns perfectly with our vision of advancing global diagnostics and supporting healthcare providers with the tools they need to deliver better patient outcomes.”

“This partnership with LGC will expand the reach of our proprietary technologies and enable more laboratories to improve the reliability of their patient testing by NGS,” added Nick Lazaridis, President of AccuGenomics. “LGC is well aligned across the diagnostic, therapeutic and pharmaceutical sectors as a strategic distribution partner. Our focus is on improving the accuracy and sensitivity of challenging NGS applications like liquid biopsy detection for MRD; this partnership with LGC will accelerate the adoption of Accukit ctDNA MRD IS, and Accukit Myeloid DNA IS. Together, we can contribute to the development of more precise life-saving diagnostic tools that support personalized medicine, leading to more accurate clinical NGS tests.”

Related Links:
LGC 
AccuGenomics


Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Gold Member
Thyroid-Stimulating Hormone Test
ULTRA-TSH
New
Gold Member
Thyroxin Test
T3 TOTAL
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Molecular Diagnostics

view channel
Image: The new study findings emphasize the need for incorporating disease heterogeneity into type 2 diabetes care strategies (Photo courtesy of Cell 2025; doi.org/10.1016/j.cell.2025.05.00)

Molecular Fingerprint for Insulin Sensitivity Could Diagnose Diabetes Before Disease Develops

Insulin is a hormone essential for regulating blood sugar levels, and its dysfunction is a key factor in the development of diabetes. Insulin resistance, a condition where the body's cells do not respond... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: Results of AI-based 3D virtual H&E staining and quantitative analysis of pathological tissue (Photo courtesy of Nature Communications, DOI:10.1038/s41467-025-59820-0)

Virtual Staining Technology Paves Way for Non-Invasive Pathological Diagnosis

For more than 200 years, traditional pathology has depended on the technique of examining cancer tissues under a microscope, a method that provides only limited, specific cross-sections of the 3D structure... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.